Comparing five advanced treatments for axial spondyloarthritis and psoriatic arthritis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will follow adults with axial spondyloarthritis or psoriatic arthritis who have begun treatment with one of five advanced therapies at participating NHS hospitals in the United Kingdom. Patients will complete surveys about symptoms, quality of life, and treatment experience during the study period. Investigators will also review participants' medical records retrospectively toward the end of follow-up to capture clinical outcomes, medication history, and healthcare use. The design is intended to provide real-world comparisons of effectiveness and patient-reported experience across these therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
* Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
* Participant is aged 18 years or older at enrolment.

Exclusion Criteria:

-Participation in a clinical trial at enrolment.

Where it's running

• Royal National Hospital for Rheumatic Diseases
  Bath, Somerset, United Kingdom Recruiting

Study contacts

• Study coordinator: SpA Extend Team
• Email: arwspaextend@adelphigroup.com
• Phone: +441625 577 829

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guselkumab versus risankizumab for moderate-to-severe Crohn's disease

  This comparison tests whether guselkumab or risankizumab works better to reduce intestinal inflammation in people with moderately to severely active Crohn's disease.

  Recruiting at 162 sites Phase 3 Janssen Research & Development, LLC · Dothan, Alabama and 163 other locations · NCT07499232

• Personalized lab test to predict the best treatment for rheumatic diseases

  This project tests a lab-based cell assay to see if it can predict which DMARD will work best for adults with autoimmune rheumatic diseases such as RA, PsA, axSpA, and GCA.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT07150000

• Second-line treatment with upadacitinib or risankizumab for adults with Crohn's disease

  This project will test how well upadacitinib or risankizumab work as second-line treatments for adults with moderate-to-severe Crohn's disease who previously used a TNF inhibitor.

  Recruiting at 25 sites AbbVie · Castellana Grotte, Bari and 24 other locations · NCT07073079

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.

  Recruiting Phase 4 Hyogo Medical University · Nishinomiya and 3 other locations · NCT07872449

• Safety and drug level study of multiple doses of upadacitinib, tofacitinib, and baricitinib in healthy adults

  This early-phase study tests how different doses of upadacitinib, tofacitinib, and baricitinib behave in healthy adults to understand safety and how the drugs act in the body.

  Recruiting Phase 1 AbbVie · Grayslake, Illinois · NCT07843693

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.